Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

Jacques De Grève*, Teresa Moran, Marie Pascale Graas, Daniella Galdermans, Peter Vuylsteke, Jean Luc Canon, Denis Schallier, Lore Decoster, Erik Teugels, Dan Massey, Vikram K. Chand, Johan Vansteenkiste

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

74 Cites (Scopus)

Fingerprint

Navegar pels temes de recerca de 'Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma'. Junts formen un fingerprint únic.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science